Featured Research

from universities, journals, and other organizations

Kinesin 'chauffeur' helps HIV escape destruction

Date:
October 22, 2012
Source:
Rockefeller University Press
Summary:
A study identifies a motor protein that ferries HIV to the plasma membrane, helping the virus escape from macrophages.

A study in The Journal of Cell Biology identifies a motor protein that ferries HIV to the plasma membrane, helping the virus escape from macrophages.

HIV reproduces inside disease-fighting T cells, killing them in the process. But the virus can also replicate in macrophages, which survive infection and serve as reservoirs of HIV. In T cells, new viral particles are formed at the plasma membrane, but in macrophages the viruses assemble inside cytoplasmic containers called virus-containing compartments (VCCs). To break out of a macrophage, a virus particle therefore has to travel to the plasma membrane.

A group of researchers led by Philippe Benaroch (INSERM, Paris) showed that the virus hitches a ride with the microtubule-based kinesin motor protein KIF3A. The researchers found that reducing the level of KIF3A dramatically reduced the release of HIV particles from macrophages. Yet the procedure did not have any effect on the amount of HIV escaping from T cells. KIF3A drives HIV along microtubules, the researchers discovered; they observed KIF3A proteins and VCCs moving in tandem along the microtubule filaments. Consistent with this, VCCs build up in cells lacking KIF3A, suggesting that their movements stall in the absence of the kinesin. How HIV exits VCCs remains uncertain, but the results indicate that inhibiting KIF3A might offer a new way to combat the virus.


Story Source:

The above story is based on materials provided by Rockefeller University Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rapha๋l Gaudin, Bruna Cunha de Alencar, Mabel Jouve, Stefano B่rre, Emmanuel Le Bouder, Michael Schindler, Aditi Varthaman, Fran็ois-Xavier Gobert, and Philippe Benaroch. Critical role for the kinesin KIF3A in the HIV life cycle in primary human macrophages. The Journal of Cell Biology, 2012; DOI: 10.1083/jcb.201201144

Cite This Page:

Rockefeller University Press. "Kinesin 'chauffeur' helps HIV escape destruction." ScienceDaily. ScienceDaily, 22 October 2012. <www.sciencedaily.com/releases/2012/10/121022092853.htm>.
Rockefeller University Press. (2012, October 22). Kinesin 'chauffeur' helps HIV escape destruction. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/10/121022092853.htm
Rockefeller University Press. "Kinesin 'chauffeur' helps HIV escape destruction." ScienceDaily. www.sciencedaily.com/releases/2012/10/121022092853.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins